MYL is benefiting from invalidation of TEVA patent on Copaxone, an MS drug. The new buy zone is $32 to $35.57. Recommended position size is 35% to 40%. The stock is trading at $38.40 as of this writing.
What To Do Now
Those in the stock may continue to hold.
Those not in the stock may consider waiting for a dip into the buy zone.